Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness of Green Tea Leaf Extract Ointment for Adults with Actinic Keratosis on the Scalp and Face

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Actinic Keratosis, a skin condition that often appears as rough, scaly patches on the skin, particularly on areas frequently exposed to the sun, like the scalp and face. The study is testing the effectiveness and safety of a treatment called Veregen 10% Ointment, which contains an active ingredient derived from green tea leaves. This ointment will be compared to a placebo, which looks similar but does not contain the active ingredient.

The purpose of the study is to determine if Veregen 10% Ointment is more effective than the placebo in completely clearing the affected skin areas. Participants will apply the ointment to the affected areas for a period of 12 weeks, followed by a 4-week observation period. During this time, the study will monitor the skin for any changes, aiming for complete disappearance of the Actinic Keratosis patches.

Throughout the study, participants will have regular check-ups to assess the condition of their skin and to ensure their safety. The study will also continue to monitor participants for a year after the treatment to observe any long-term effects or recurrence of the skin condition. This trial aims to provide valuable information on the potential benefits of using Veregen 10% Ointment for treating Actinic Keratosis on the scalp and face.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient is required to provide written informed consent, confirming their willingness to participate.

    The patient must be at least 18 years old and have a clinically confirmed diagnosis of mild to moderate actinic keratosis on the face or bald scalp.

  2. Step 2

    Treatment period

    The patient will apply Veregen 10% ointment or a placebo ointment to the affected area. The ointment is applied topically, meaning it is used directly on the skin.

    The treatment period lasts for 12 weeks. During this time, the patient will have on-site visits at 2, 4, 8, and 12 weeks to monitor progress.

  3. Step 3

    Post-treatment period

    After completing the 12-week treatment, there is a 4-week post-treatment period. This period allows for further observation of the treatment's effects.

    The primary goal is to achieve complete clearance of the actinic keratosis lesions in the treated area.

  4. Step 4

    Follow-up period

    Following the post-treatment period, a 1-year follow-up period is conducted to monitor the long-term effects of the treatment.

    During this time, the patient will have visits at 8 weeks post-treatment, and then at 3, 6, 9, and 12 months post-treatment.

  5. Step 5

    Safety and efficacy assessments

    Throughout the study, the patient will be assessed for any adverse events or side effects related to the treatment.

    The efficacy of the treatment will be evaluated by measuring the reduction or clearance of actinic keratosis lesions.

Who can join the trial?

6 criteria

  • Patients must be willing to participate and provide written consent, which means they agree to join the study after understanding what it involves.
  • Participants can be male or female and must be at least 18 years old.
  • Participants need to have a confirmed diagnosis of mild to moderate **Actinic Keratosis (AK)**, which is a skin condition, on the face (including the forehead but not the eyelids, lips, or inside the mouth) and/or the bald scalp.
  • Participants should have between 4 and 8 separate **AK lesions**, which are small areas of skin damage, in a treatment area on the face and/or bald scalp that is 25 square centimeters in size.
  • The **AK lesions** in the treatment area must be typical and classified as **Olsen grade I** or **Olsen grade II**, which are specific types of this skin condition.
  • Participants must be able to follow the study instructions and are likely to complete all the study requirements.

Who cannot join the trial?

8 criteria

  • Patients who do not have Actinic Keratosis (AK) on the scalp or face cannot participate. Actinic Keratosis is a rough, scaly patch on the skin caused by sun exposure.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not willing or able to follow the study procedures and requirements cannot participate.
  • Patients who have other medical conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients who have used certain medications or treatments that might affect the study results cannot participate.
  • Patients who have a history of allergic reactions to the study medication or similar products cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sinecatechins: This is an ointment made from a defined extract of green tea leaves. It is used in this study to treat actinic keratosis, which is a skin condition that can develop into cancer if left untreated. The ointment is applied to the affected areas on the scalp and face to see if it can completely clear the condition after a 12-week treatment period, with an additional 4-week follow-up.

What is already known about the treatment

Veregen – This medication is an ointment applied topically to the skin, specifically designed for use on the scalp and face. It is currently being studied in clinical trials for its effectiveness in treating actinic keratosis, a skin condition caused by sun damage. The main therapeutic indication is to achieve complete clearance of the affected skin areas. Veregen works by utilizing sinecatechins, a defined extract of green tea leaves, which have antioxidant properties that help in reducing abnormal skin cell growth. It is classified as a topical dermatological agent.

Investigated diseases

Actinic Keratosis – Actinic Keratosis is a skin condition characterized by rough, scaly patches on areas of the skin that have been exposed to the sun, such as the scalp and face. It occurs when skin cells are damaged by ultraviolet (UV) radiation, leading to abnormal growth. The patches can vary in color, appearing pink, red, or brown, and may feel dry or rough to the touch. Over time, these lesions can become more pronounced and may increase in number. While they are generally not painful, they can cause discomfort or itching. If left untreated, there is a potential for these lesions to develop into more serious skin conditions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502811-12-00Protocol codePro_VER-01-21_AREstimated enrolment280 patientsSponsorAresus Pharma GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).